高克非,冯艳玲,黄永文.三氧化二砷联合抗坏血酸对高转移性卵巢癌细胞系HO-8910PM的抗肿瘤实验研究[J].中国肿瘤,2014,23(6):518-522.
三氧化二砷联合抗坏血酸对高转移性卵巢癌细胞系HO-8910PM的抗肿瘤实验研究
The Research on Anti-cancer Effect of Arsenic Trioxide Combined with Ascorbic Acid on Highly Metastatic Ovarian Carcinoma Cell line HO-8910PM
投稿时间:2013-11-02  
DOI:10.11735/j.issn.1004-0242.2014.06.A016
中文关键词:  三氧化二砷  抗坏血酸  化疗  卵巢癌
英文关键词:arsenic trioxide  ascorbic acid  chemotherapy  ovarian carcinoma
基金项目:
作者单位
高克非 广州中医药大学第一附属医院 
冯艳玲 中山大学肿瘤防治中心/华南肿留学国家重点实验室 
黄永文 中山大学肿瘤防治中心/华南肿留学国家重点实验室 
摘要点击次数: 1731
全文下载次数: 955
中文摘要:
      摘 要:[目的] 在高转移性上皮性卵巢癌细胞株HO-8910PM中观察AS2O3联合抗坏血酸(Vitamin C)的抗肿瘤效应。[方法] 本研究以高转移性上皮性卵巢癌细胞株HO-8910PM为研究对象,以MTT药敏实验、流式细胞仪以及Western-blot方法检测AS2O3和Vitamin C单药及联合的抗肿瘤效应及其机制。[结果] AS2O3和Vitamin C单药对HO-8910PM细胞株均具有剂量依赖性的生长抑制作用。AS2O3 联合Vitamin C后具有明显的协同抗肿瘤效应,并且出现S期阻滞效应。Western-blot结果显示,AS2O3和Vitamin C联合作用后,凋亡抑制蛋白bcl-2和凋亡促进蛋白bax分别进一步表达下调和上调。[结论] 对高转移性的上皮性卵巢癌细胞株,Vitamin C和AS2O3单药均具较好的抗肿瘤效应,Vitamin C对AS2O3有较好的化疗增敏效应,两者的联合应用值得在卵巢癌方面进一步研究探讨。
英文摘要:
      Abstract:[Purpose] To investigate the anti-cancer effect of arsenic trioxide(AS2O3) combined with Vitamin C on highly metastatic ovarian carcinoma cell line HO-8910PM.[Methods] In HO-8910PM cells,the anti-cancer effects of Vitamin C or AS2O3 applied as a single agent were observed,and the sensitizing effects of Vitamin C when it was used in the combination with AS2O3 were observed. The anti-cancer effect of AS2O3 or Vitamin C and their mechanisms were analyzed by MTT chemosensitivity test,flow cytometry and Western-blot method.[Results] Dose-dependent antiproliferative effect on HO-8910PM cells were observed when Vitamin C or AS2O3 was applied as single agent. Vitamin C had sensitizing effect on AS2O3. Vitamin C combined with AS2O3 leads to significant S-phase block. The expression of inhibitor-of-apoptosis protein bcl-2 was down-regulated,and the promoter of apoptosis protein bax was up-regulated.[Conclusions] Both AS2O3 and Vitamin C have anti-cancer effects on HO-8910PM cells. Vitamin C has sensitizing effect on Vitamin C when they were used in highly metastatic ovarian carcinoma cells. The combination of the two agents is a promising regimen which is worth on-going study in epithelial ovarian cancer.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器